ESMO 2020: Abemaciclib Improves Invasive Disease-Free Survival and Reduces Risk of Metastasis in High-Risk Hormone Receptor-Positive, HER2-Negative Breast Cancer
Expert suggests the findings could be practice-changing
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.